Informations:
Erreur:
ID
23883
Description
Study part: Eligibility Question Visit 1. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381
Mots-clés
Versions (1)
- 16/07/2017 16/07/2017 -
Détendeur de droits
GlaxoSmithKline
Téléchargé le
16 juillet 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Question Visit 1 Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381
Eligibility Question Visit 1
- StudyEvent: ODM
Similar models
Eligibility Question Visit 1
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Subject Number
Item
Subject Number
integer
C2348585 (UMLS CUI [1])
entry criteria
Item
Did the subject meet all the entry criteria ?
boolean
C1516637 (UMLS CUI [1])
compliance
Item
Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
boolean
C1321605 (UMLS CUI [1])
gender; age
Item
A male or female between, and including, 12 and 18 months of age at the time of the booster vaccination.
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
informed consent
Item
Written informed consent obtained from the parent(s) or guardian(s) of the subject.
boolean
C0021430 (UMLS CUI [1])
comorbidity; medical history; clinical examination
Item
Free of obvious health problems as established by medical history and clinical examination before entering into the study.
boolean
C0009488 (UMLS CUI [1])
C0262926 (UMLS CUI [2])
C1456356 (UMLS CUI [3])
C0262926 (UMLS CUI [2])
C1456356 (UMLS CUI [3])
study participation status
Item
Having participated in the primary vaccination study 792014/003.
boolean
C2348568 (UMLS CUI [1])
concomitant medication
Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the booster of study vaccine, or planned use during the study period.
boolean
C2347852 (UMLS CUI [1])
chronic drug usage immunosuppressants corticosteroids
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose. (For corticosteroids, this will mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
boolean
C0598327 (UMLS CUI [1,1])
C0021081 (UMLS CUI [1,2])
C0001617 (UMLS CUI [1,3])
C0021081 (UMLS CUI [1,2])
C0001617 (UMLS CUI [1,3])
vaccine administration
Item
Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the booster dose of vaccine(s).
boolean
C2368628 (UMLS CUI [1])
Immunization
Item
Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, polio, Hib and/or meningococcal serogroup C or Y disease except if within the framework of study 792014/003.
boolean
C0020971 (UMLS CUI [1])
vaccination pneumococcal disease
Item
Previous vaccination against pneumococcal disease.
boolean
C0042196 (UMLS CUI [1,1])
C0032269 (UMLS CUI [1,2])
C0032269 (UMLS CUI [1,2])
medical history diphtheria tetanus pertussis
Item
History of diphtheria, tetanus, pertussis, hepatitis B, polio, Hib and/or meningococcal serogroup C or Y disease.
boolean
C0262926 (UMLS CUI [1,1])
C0012546 (UMLS CUI [1,2])
C0039614 (UMLS CUI [1,3])
C0043167 (UMLS CUI [1,4])
C0012546 (UMLS CUI [1,2])
C0039614 (UMLS CUI [1,3])
C0043167 (UMLS CUI [1,4])
exposure (to) disease diphtheria tetanus pertussis
Item
Known exposure to diphtheria, tetanus, pertussis, hepatitis B, polio, Hib and/or meningococcal serogroup C or Y disease within the last 3 months.
boolean
C0848543 (UMLS CUI [1,1])
C0012546 (UMLS CUI [1,2])
C0039614 (UMLS CUI [1,3])
C0043167 (UMLS CUI [1,4])
C0012546 (UMLS CUI [1,2])
C0039614 (UMLS CUI [1,3])
C0043167 (UMLS CUI [1,4])
immunodeficient condition HIV infection
Item
Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
boolean
C3829792 (UMLS CUI [1,1])
C0019693 (UMLS CUI [1,2])
C0019693 (UMLS CUI [1,2])
Congenital immunodeficiency disease
Item
A family history of congenital or hereditary immunodeficiency.
boolean
C0272229 (UMLS CUI [1])
Hypersensitivity
Item
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
boolean
C0020517 (UMLS CUI [1])
Chronic disease
Item
Major congenital defects or serious chronic illness.
boolean
C0008679 (UMLS CUI [1])
neurologic disorders seizures
Item
History of any neurologic disorders or seizures including febrile seizures in infancy.
boolean
C0027765 (UMLS CUI [1,1])
C0036572 (UMLS CUI [1,2])
C0036572 (UMLS CUI [1,2])
Acute disease diarrhoea respiratory infection
Item
Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low- grade febrile illness, i.e., Axillary temperature <37.5°C / Rectal temperature <38°C)
boolean
C0001314 (UMLS CUI [1,1])
C0011991 (UMLS CUI [1,2])
C0035243 (UMLS CUI [1,3])
C0011991 (UMLS CUI [1,2])
C0035243 (UMLS CUI [1,3])
immunoglobulins
Item
Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
boolean
C0021027 (UMLS CUI [1])